NasdaqGS:INDVPharmaceuticals
Indivior (NasdaqGS:INDV): Reassessing Valuation After Positive SUBLOCADE and INDV-2000 Clinical Trial Results
Indivior (NasdaqGS:INDV) just gave investors fresh reasons to revisit the stock, with new clinical data on SUBLOCADE and Phase II results for INDV-2000 underscoring progress in treating high risk opioid use disorder.
See our latest analysis for Indivior.
Those encouraging readouts help explain why Indivior’s 90 day share price return sits at 51.31 percent and its 1 year total shareholder return is 201.97 percent, suggesting momentum is building around the story.
If this kind of clinical...